Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apixaban versus warfarin for microRNA modulation in atrial fibrillation
2015-002755-94Phase 4Terminated
- Sponsor
- Policlinico Gemelli
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in Atrial fibrillation (AFib) comparing Eliquis arm with Coumadin arm (2 arms). Primary endpoint: Differential expression of top three coagulation-related microRNAs. Started Feb 2021; status: terminated.
02
Drugs
apixabanwarfarin
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on 2015-002755-94.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002755-94.